Questioning Lipid Nanoparticles
Since there isn’t a good article which 1) scientifically, 2) clinically and 3) regulatorily address Lipid Nanoparticles (LNPs) and the FDA’s role in assuring and regulating novel technologies and ingredients, I am writing one.